Spinal cord stimulation for RSD: success rates and risks
Reflex sympathetic dystrophy (RSD), now commonly called complex regional pain syndrome type I (CRPS-I), can cause burning pain, unusual sensitivity, swelling, skin-color changes, temperature differences, and reduced movement. Symptoms may begin after an injury or procedure and persist even after tissues appear to have healed.
When medication, physical therapy, nerve blocks, and other treatments do not provide enough relief, spinal cord stimulation (SCS) may be considered. This therapy uses mild electrical impulses to alter pain signaling before it reaches the brain. It does not repair the original nerve problem, and outcomes vary considerably.
A careful decision requires more than a promising percentage from a study. The location and duration of pain, functional limitations, mental health, medication use, and response to a temporary trial all affect whether an implanted device is worthwhile.
What RSD means for treatment decisions
RSD is a nervous-system pain disorder involving abnormal processing by peripheral nerves, the spinal cord, and the brain. Pain may remain intense after a relatively minor injury, while touch, movement, or temperature changes can trigger symptoms. Some people develop stiffness, weakness, sweating changes, or muscle and bone changes over time.
Symptoms can also extend beyond the original area. Learning about patterns of spread may help patients recognize why pain distribution can change and why early reassessment matters. A wider symptom pattern does not automatically mean SCS will be ineffective, but it can complicate treatment planning.
The goal of stimulation is usually meaningful pain reduction and better function, such as walking farther, sleeping more consistently, or participating in rehabilitation. Complete pain elimination is uncommon and should not be presented as the expected result.
How spinal cord stimulation works
An SCS system generally includes thin leads positioned in the epidural space near the spinal cord and a small pulse generator placed under the skin. Traditional systems create a tingling sensation called paresthesia. Newer approaches may use high-frequency or burst stimulation, which can reduce pain with little or no perceived tingling.
Before permanent implantation, most patients undergo a trial lasting several days. Temporary leads are connected to an external generator, allowing the patient and care team to assess pain relief, activity, sleep, and side effects. A permanent device is usually considered only when the trial produces clinically useful improvement.
SCS works best as part of a broader plan. Physical rehabilitation, desensitization, medication review, sleep care, and psychological support remain important because reducing pain does not automatically restore strength or mobility.
What success rates really measure
Research on SCS for CRPS has reported different outcomes depending on the device, study design, follow-up period, and definition of success. Some studies describe at least 50% pain relief in a substantial portion of carefully selected patients, while others show more modest benefits over time. Relief may decline as the nervous system adapts or as hardware problems develop.
Dorsal root ganglion (DRG) stimulation is another neuromodulation approach. It targets nerve roots connected to a specific painful region and may be useful for focal foot, ankle, knee, or groin pain. It is not automatically better than conventional SCS for every person, and availability, experience, insurance coverage, and anatomy all influence the choice.
| Outcome or issue | What patients may reasonably expect |
|---|---|
| Pain relief | Meaningful reduction is possible, but complete relief is uncommon |
| Function | Walking, sleep, and daily activity may improve when pain decreases |
| Durability | Benefits can persist, though some people experience declining relief |
| Trial period | A temporary trial helps test effectiveness before implantation |
| Medication use | Some patients reduce medicines, but stopping them is not guaranteed |
| Revision risk | Lead migration, battery problems, or loss of benefit may require another procedure |
Reported “success” can therefore mean different things. A study may count a specified percentage of pain relief, while a patient may define success as returning to work or tolerating physical therapy. These goals should be discussed before a trial begins.
Risks and tradeoffs
Implantation carries ordinary procedural risks, including bleeding, infection, wound problems, allergic reaction, and discomfort at the generator site. A lead can move out of position, break, or stop producing the intended coverage. Batteries eventually need replacement, and some rechargeable systems require regular maintenance.
Less common complications include spinal fluid leakage, headache, nerve irritation, and damage to nearby structures. Serious neurological injury is rare, but it is a recognized risk. Infection involving the implanted hardware may require antibiotics and removal of some or all of the system.
There are also non-surgical drawbacks. Stimulation may provide incomplete or inconsistent relief, and the device may be uncomfortable during certain activities or interfere with imaging unless the system is approved for that scan. Future procedures can be needed for reprogramming, revision, replacement, or removal.
Who may be a candidate
Candidates typically have a well-supported CRPS diagnosis, persistent symptoms, and inadequate improvement with appropriate conservative care. A specialist may review prior treatments, imaging, neurological findings, medication history, substance use, sleep, and the patient’s ability to participate in rehabilitation.
Psychological assessment is often part of the process. This does not mean the pain is considered imaginary. The evaluation identifies depression, anxiety, trauma, unrealistic expectations, medication-related concerns, or barriers that could affect recovery and long-term device use.
Active infection, uncontrolled bleeding risk, untreated severe psychiatric illness, inability to follow device instructions, or an unclear diagnosis may delay or prevent implantation. The final decision should come from a multidisciplinary team familiar with neuromodulation and CRPS.
Preparing for a specialist visit
A practical appointment focuses on measurable goals rather than a single pain score. Patients can bring a medication list, procedure history, imaging reports, and a short record showing how symptoms affect walking, sleep, work, exercise, and personal care.
Useful points to discuss include:
- Which stimulation method best fits the location and pattern of pain
- How the temporary trial will be judged and how long it will last
- Expected pain relief, functional gains, and medication changes
- Infection, lead migration, revision, removal, and battery-related risks
- MRI access, driving restrictions, device care, and follow-up programming
It is also helpful to ask how the team handles a failed trial or loss of benefit. Understanding alternatives, out-of-pocket costs, insurance requirements, and the rehabilitation plan can prevent rushed decisions.
Making a careful treatment decision
SCS can be a valuable option for selected people with treatment-resistant RSD, but success depends on diagnosis, pain distribution, realistic goals, trial results, and ongoing rehabilitation. The procedure should be viewed as one component of care rather than a guaranteed cure.
Anyone considering implantation should review the evidence and personal risks with a qualified pain specialist, neurologist, or neurosurgeon. A structured evaluation and temporary trial can provide more useful information than general success statistics and help guide a decision that supports both pain control and daily function.